

**Improving health and viability in
mitochondrial disease through
inhibition of cytosolic translation
and autophagy**



Peng M. et al.

Supplemental Files

Fig S1. Effects of RC inhibition, probucol, and nutrients on AMPK activation.

MOUSE LIVER

MOUSE LIVER



HUMAN PODOCYTES










Table S1. Table of all lifespan results in *C. elegans gas-1(fc21)* worms treated with probucol, rapamycin, and cycloheximide

| STUDY DRUG | Concentration | Buffer | Worm Stage at Treatment Initiation | Worm # Studied | Experimental Replicate # | Study Date | Lifespan Percent Change Relative to Untreated <i>gas-1</i> Median | p value vs <i>gas-1</i> | p value vs N2 | NOTES |
|---------------|---------------|-----------|------------------------------------|----------------|--------------------------|------------|---|-------------------------|---------------|------------|
| Probucol | 5 mM | 2.7% DMSO | Dev | 60 | 1 | Oct-12 | NA | NA | NA | TOXIC DMSO |
| | 5 mM | 2.7% DMSO | YA | 60 | 1 | Oct-12 | NA | NA | NA | TOXIC DMSO |
| | 500 uM | Ethanol | Dev | 60 | 1 | Dec-12 | 85 | < 0.0001 | < 0.0001 | |
| | 500 uM | Ethanol | YA | 60 | 1 | Dec-12 | 85 | 0.0869 | < 0.0001 | |
| | 50 uM | Ethanol | Dev | 60 | 1 | Mar-13 | 117 | 0.0034 | 0.3994 | |
| | 50 uM | Ethanol | YA | 60 | 1 | Mar-13 | 108 | 0.0354 | 0.0961 | |
| | 5 uM | Ethanol | Dev | 60 | 1 | Mar-13 | 133 | < 0.0001 | 0.4285 | |
| | 5 uM | Ethanol | YA | 60 | 1 | Mar-13 | 108 | 0.0003 | 0.894 | |
| Rapamycin | 2.5 uM | Ethanol | Dev | 56 | 1 | Dec-12 | 85 | < 0.0001 | < 0.0001 | |
| | 2.5 uM | Ethanol | YA | 60 | 1 | Dec-12 | 85 | 0.0025 | < 0.0001 | |
| | 250 nM | Ethanol | Dev | 56 | 1 | Dec-12 | 85 | 0.0157 | < 0.0001 | |
| | 250 nM | Ethanol | YA | 56 | 1 | Dec-12 | 85 | 0.0313 | < 0.0001 | |
| | 25 nM | Ethanol | Dev | 56 | 1 | Dec-12 | 100 | 0.5081 | < 0.0001 | |
| | 25 nM | Ethanol | YA | 60 | 1 | Dec-12 | 100 | 0.648 | < 0.0001 | |
| | 25 nM | Ethanol | Dev | 59 | 2 | Mar-13 | 100 | 0.114 | 0.0419 | |
| | 25 nM | Ethanol | YA | 58 | 2 | Mar-13 | 92 | 0.9537 | 0.0005 | |
| | 2.5 nM | Ethanol | Dev | 54 | 1 | Mar-13 | 117 | 0.0151 | 0.133 | |
| | 2.5 nM | Ethanol | YA | 57 | 1 | Mar-13 | 107 | 0.0066 | 0.1154 | |
| | 2.5 nM | Ethanol | Dev | 60 | 2 | Aug-14 | 100 | 0.512 | < 0.0001 | |
| | 2.5 nM | Ethanol | YA | 60 | 2 | Aug-14 | 100 | 0.0689 | < 0.0001 | |
| | 2.5 nM | Ethanol | YA | 60 | 3 | Sep-14 | 100 | 0.7236 | < 0.0001 | |
| 250 pM | Ethanol | Dev | 60 | 1 | Sep-14 | 82 | 0.0096 | < 0.0001 | | |
| Cycloheximide | 2.5 uM | Water | Dev | 60 | 1 | Jul-14 | 82 | 0.0006 | < 0.0001 | |
| | 2.5 uM | Water | YA | 60 | 1 | Aug-14 | 100 | 0.1294 | < 0.0001 | |
| | 250 nM | Water | YA | 60 | 1 | Aug-14 | 100 | 0.8881 | < 0.0001 | |
| | 250 nM | Water | YA | 60 | 2 | Sep-14 | 100 | 0.4995 | < 0.0001 | |
| | 25 nM | Water | YA | 60 | 1 | Aug-14 | 118 | 0.3689 | < 0.0001 | |
| | 25 nM | Water | Dev | 60 | 1 | Sep-14 | 100 | 0.7099 | < 0.0001 | |

*Dev, Development; YA, young adult day 1

Fig S2. Probucol effects on lifespan of *C. elegans gas-1(fc21)* CI deficient worms







Fig S3. Rapamycin effects on lifespan of *C. elegans gas-1(fc21)* CI deficient worms







Fig S4. Cycloheximide effects on *C. elegans* lifespan of *gas-1(fc21)* CI deficient worms




Fig S5. Cytosolic translation activity effects in human podocytes.





Fig S6. Cycloheximide effects in CIII (Antimycin A) or CV (oligomycin) inhibition & in CI-III (FBXL4) disease







Fig S7. Cycloheximide effects on mitochondrial physiology in human cells with pharmacologic or genetic based RC deficiencies.









Fig S8. Apoptosis is induced only by high-dose, short-duration rotenone

| | <u>Human Podocytes</u> 11 mM glucose | | | | | | | |
|------------------------|---|------|-----|-----|---|----|----|-----|
| Time (hours) | - | 24 | 24 | 6 | 6 | 24 | 6 | 6 |
| Hydrogen Peroxide (mM) | - | - | - | - | - | 1 | 10 | 100 |
| Rotenone (uM) | - | 0.05 | 0.1 | 0.5 | 1 | - | - | - |

Cleaved CASP9 (37 kDa)



Cleaved PARP (89 kDa)




Fig S9. Mitophagy is activated in *FBXL4* deficient patient fibroblasts with RC complex I-III dysfunction.





Fig S10. Chloramphenicol effects on cell viability with RC inhibition and therapies





Fig S11. Long-term (24-48 hours) mitochondrial RC inhibition activates the ER stress response (GRP78 and PERK) in human podocytes and is prevented by cycloheximide.





Fig S12. Short-term mitochondrial RC inhibition induces the ER stress response (PERK and phosphor-EIF2 α) in human podocytes.





Fig S13. Gene expression profiling in *C. elegans gas-1(fc21)* adult worms following 24 treatment with (A) 5 μ M probucol and (B-C) 2.5 μ M cycloheximide






Fig S14. Pathway-level RNAseq transcriptome effects of treating *C. elegans gas-1(fc21)* mutant adult worms with cycloheximide, probucol or rapamycin.

A Cycloheximide effects in *gas-1(fc21)*

| UPREGULATED by CHX in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|------------------------------------|-----------------|---------------|-----------------|-----------------------|----------|--------|---|
| 1 | cel02010 | 16 | 16 | 2.03 | 7.85E-05 | 0.71% | ABC transporters |
| 2 | cel03010 | 142 | 115 | 1.61 | 9.49E-04 | 4.27% | Ribosome |
| 3 | cel04350 | 34 | 32 | 1.5 | 1.86E-03 | 5.57% | TGF-beta signaling pathway |
| 4 | cel04310 | 58 | 56 | 1.26 | 6.57E-03 | 14.78% | Wnt signaling pathway |
| 5 | cel04141 | 124 | 119 | 0.81 | 5.56E-02 | 92.23% | Protein processing in endoplasmic reticulum |
| 6 | cel03030 | 32 | 30 | 0.76 | 6.75E-02 | 92.23% | DNA replication |
| 7 | cel00350 | 22 | 21 | 0.73 | 7.67E-02 | 92.23% | Tyrosine metabolism |
| 8 | cel03040 | 106 | 102 | 0.65 | 1.05E-01 | 92.23% | Spliceosome |
| 9 | cel03060 | 21 | 20 | 0.63 | 1.12E-01 | 92.23% | Protein export |
| 10 | cel03008 | 79 | 58 | 0.61 | 1.17E-01 | 92.23% | Ribosome biogenesis in eukaryotes |
| 11 | cel03018 | 44 | 43 | 0.54 | 1.48E-01 | 92.23% | RNA degradation |
| 12 | cel00970 | 113 | 32 | 0.48 | 1.76E-01 | 92.23% | Aminoacyl-tRNA biosynthesis |
| 13 | cel00590 | 13 | 13 | 0.45 | 1.90E-01 | 92.23% | Arachidonic acid metabolism |
| 14 | cel00600 | 25 | 24 | 0.44 | 1.96E-01 | 92.23% | Sphingolipid metabolism |
| 15 | cel04145 | 56 | 55 | 0.38 | 2.28E-01 | 92.23% | Phagosome |

| DOWNREGULATED by CHX in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|--------------------------------------|-----------------|---------------|-----------------|-----------------------|----------|--------|---|
| 1 | cel01040 | 15 | 14 | -1.78 | 4.03E-04 | 3.62% | Biosynthesis of unsaturated fatty acids |
| 2 | cel00190 | 111 | 98 | -1.14 | 1.31E-02 | 59.02% | Oxidative phosphorylation |
| 3 | cel00520 | 32 | 30 | -1.06 | 1.99E-02 | 59.66% | Amino sugar and nucleotide sugar metabolism |
| 4 | cel04146 | 60 | 59 | -0.95 | 3.09E-02 | 59.66% | Peroxisome |
| 5 | cel00450 | 11 | 10 | -0.93 | 3.96E-02 | 59.66% | Selenocompound metabolism |
| 6 | cel00051 | 23 | 22 | -0.87 | 4.28E-02 | 59.66% | Fructose and mannose metabolism |
| 7 | cel00500 | 26 | 25 | -0.87 | 4.64E-02 | 59.66% | Starch and sucrose metabolism |
| 8 | cel00380 | 29 | 27 | -0.79 | 6.19E-02 | 62.71% | Tryptophan metabolism |
| 9 | cel04140 | 15 | 15 | -0.8 | 6.27E-02 | 62.71% | Regulation of autophagy |
| 10 | cel00062 | 15 | 14 | -0.72 | 8.20E-02 | 70.21% | Fatty acid elongation |
| 11 | cel04020 | 37 | 37 | -0.68 | 9.09E-02 | 70.21% | Calcium signaling pathway |
| 12 | cel00260 | 26 | 26 | -0.68 | 9.36E-02 | 70.21% | Glycine, serine and threonine metabolism |

C Rapamycin effects in *gas-1(fc21)*

| UPREGULATED by RAPA in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|-------------------------------------|-----------------|---------------|-----------------|-----------------------|----------|--------|-----------------------------|
| 1 | cel04145 | 56 | 55 | 0.93 | 3.33E-02 | 97.55% | Phagosome |
| 2 | cel03050 | 38 | 37 | 0.72 | 7.87E-02 | 97.55% | Proteasome |
| 3 | cel00590 | 13 | 13 | 0.71 | 8.40E-02 | 97.55% | Arachidonic acid metabolism |

| DOWNREGULATED by RAPA in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|---------------------------------------|-----------------|---------------|-----------------|-----------------------|----------|--------|--|
| 1 | cel00982 | 36 | 35 | -1.29 | 6.27E-03 | 56.39% | Drug metabolism - cytochrome P450 |
| 2 | cel03020 | 24 | 23 | -0.93 | 3.54E-02 | 61.93% | RNA polymerase |
| 3 | cel03010 | 142 | 115 | -0.87 | 4.31E-02 | 61.93% | Ribosome |
| 4 | cel04120 | 77 | 73 | -0.87 | 4.45E-02 | 61.93% | Ubiquitin mediated proteolysis |
| 5 | cel04080 | 24 | 24 | -0.83 | 5.13E-02 | 61.93% | Neuroactive ligand-receptor interaction |
| 6 | cel04140 | 15 | 15 | -0.81 | 6.13E-02 | 61.93% | Regulation of autophagy |
| 7 | cel00040 | 20 | 19 | -0.78 | 6.48E-02 | 61.93% | Pentose and glucuronate interconversions |
| 8 | cel00450 | 11 | 10 | -0.78 | 6.83E-02 | 61.93% | Selenocompound metabolism |
| 9 | cel04310 | 58 | 56 | -0.75 | 7.38E-02 | 61.93% | Wnt signaling pathway |
| 10 | cel04020 | 37 | 37 | -0.73 | 7.56E-02 | 61.93% | Calcium signaling pathway |
| 11 | cel00980 | 32 | 31 | -0.7 | 8.71E-02 | 61.93% | Metabolism of xenobiotics by cytochrome P450 |
| 12 | cel03040 | 106 | 102 | -0.67 | 9.35E-02 | 61.93% | Spliceosome |


D Consistent pathway-level effects in *gas-1(fc21)* by all 3 drugs (depicted for Probuclol)

B Probuclol effects in *gas-1(fc21)*

| UPREGULATED by Probuclol in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|--|-----------------|---------------|-----------------|-----------------------|----------|--------|---|
| 1 | cel04145 | 56 | 55 | 1.55 | 1.36E-03 | 12.23% | Phagosome |
| 2 | cel03022 | 33 | 32 | 0.84 | 5.13E-02 | 97.95% | Basal transcription factors |
| 3 | cel03030 | 32 | 30 | 0.79 | 6.10E-02 | 97.95% | DNA replication |
| 4 | cel04130 | 23 | 23 | 0.74 | 7.61E-02 | 97.95% | SNARE interactions in vesicular transport |
| 5 | cel00590 | 13 | 13 | 0.74 | 8.16E-02 | 97.95% | Arachidonic acid metabolism |
| 6 | cel03018 | 44 | 43 | 0.71 | 8.39E-02 | 97.95% | RNA degradation |
| 7 | cel03420 | 33 | 33 | 0.69 | 8.92E-02 | 97.95% | Nucleotide excision repair |
| 8 | cel00770 | 11 | 11 | 0.71 | 9.18E-02 | 97.95% | Pantothenate and CoA biosynthesis |

| DOWNREGULATED by Probuclol in <i>gas-1</i> | KEGG Pathway ID | # Genes Total | #Genes Measured | Enrichment Score (ES) | P Value | FDR | KEGG Pathway Name |
|--|-----------------|---------------|-----------------|-----------------------|----------|--------|--|
| 1 | cel00982 | 36 | 35 | -2.15 | 1.88E-05 | 0.17% | Drug metabolism - cytochrome P450 |
| 2 | cel00071 | 44 | 41 | -1.58 | 9.86E-04 | 4.44% | Fatty acid degradation |
| 3 | cel00980 | 32 | 31 | -1.39 | 3.94E-03 | 8.11% | Metabolism of xenobiotics by cytochrome P450 |
| 4 | cel04020 | 37 | 37 | -1.34 | 3.98E-03 | 8.11% | Calcium signaling pathway |
| 5 | cel00062 | 15 | 14 | -1.42 | 4.50E-03 | 8.11% | Fatty acid elongation |
| 6 | cel01040 | 15 | 14 | -1.34 | 6.41E-03 | 8.53% | Biosynthesis of unsaturated fatty acids |
| 7 | cel00061 | 13 | 12 | -1.29 | 6.63E-03 | 8.53% | Fatty acid biosynthesis |
| 8 | cel04146 | 60 | 59 | -1.23 | 8.69E-03 | 9.78% | Peroxisome |
| 9 | cel00900 | 15 | 13 | -1.23 | 1.12E-02 | 11.20% | Terpenoid backbone biosynthesis |
| 10 | cel00830 | 18 | 18 | -1.16 | 1.38E-02 | 12.38% | Retinol metabolism |
| 11 | cel00350 | 22 | 21 | -1.04 | 2.29E-02 | 18.70% | Tyrosine metabolism |
| 12 | cel00650 | 20 | 19 | -1.01 | 2.71E-02 | 20.29% | Butanoate metabolism |
| 13 | cel00040 | 20 | 19 | -1 | 3.03E-02 | 20.96% | Pentose and glucuronate interconversions |
| 14 | cel00051 | 23 | 22 | -0.91 | 3.80E-02 | 23.12% | Fructose and mannose metabolism |
| 15 | cel04122 | 12 | 11 | -0.93 | 3.85E-02 | 23.12% | Sulfur relay system |
| 16 | cel00010 | 39 | 33 | -0.9 | 4.46E-02 | 23.63% | Glycolysis / Gluconeogenesis |
| 17 | cel04140 | 15 | 15 | -0.9 | 4.46E-02 | 23.63% | Regulation of autophagy |
| 18 | cel00500 | 26 | 25 | -0.83 | 5.90E-02 | 29.50% | Starch and sucrose metabolism |
| 19 | cel00020 | 33 | 31 | -0.79 | 6.59E-02 | 31.21% | Citrate cycle (TCA cycle) |
| 20 | cel04010 | 64 | 62 | -0.71 | 8.06E-02 | 36.29% | MAPK signaling pathway |
| 21 | cel00380 | 29 | 27 | -0.68 | 9.36E-02 | 36.82% | Tryptophan metabolism |
| 22 | cel00280 | 40 | 38 | -0.69 | 9.38E-02 | 36.82% | Valine, leucine and isoleucine degradation |
| 23 | cel00920 | 14 | 14 | -0.68 | 9.41E-02 | 36.82% | Sulfur metabolism |

'PHAGOSOME' UPREGULATION



'REGULATION OF AUTOPHAGY' DOWNREGULATION

